Unknown

Dataset Information

0

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).


ABSTRACT: Genome-wide genotyping data are increasingly available for pharmacogenetic association studies, but application of these data for development of prediction models is limited. Prediction methods, such as elastic net regularization, have recently been applied to genetic studies but only limitedly to pharmacogenetic outcomes. An elastic net was applied to a pharmacogenetic study of progression-free survival (PFS) of 468 patients with advanced breast cancer in a clinical trial of paclitaxel, nab-paclitaxel, and ixabepilone. A final model included 13 single nucleotide polymorphisms (SNPs) in addition to clinical covariates (prior taxane status, hormone receptor status, disease-free interval, and presence of visceral metastases) with an area under the curve (AUC) integrated over time of 0.81, an increase compared to an AUC of 0.64 for a model with clinical covariates alone. This model may be of value in predicting PFS with microtubule targeting agents and may inform reverse translational studies to understand differential response to these drugs.

SUBMITTER: Rashkin SR 

PROVIDER: S-EPMC6379108 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).

Rashkin Sara R SR   Chua Katherina C KC   Ho Carol C   Mulkey Flora F   Jiang Chen C   Mushiroda Tasei T   Kubo Michiaki M   Friedman Paula N PN   Rugo Hope S HS   McLeod Howard L HL   Ratain Mark J MJ   Castillos Francisco F   Naughton Michael M   Overmoyer Beth B   Toppmeyer Deborah D   Witte John S JS   Owzar Kouros K   Kroetz Deanna L DL  

Clinical pharmacology and therapeutics 20181101 3


Genome-wide genotyping data are increasingly available for pharmacogenetic association studies, but application of these data for development of prediction models is limited. Prediction methods, such as elastic net regularization, have recently been applied to genetic studies but only limitedly to pharmacogenetic outcomes. An elastic net was applied to a pharmacogenetic study of progression-free survival (PFS) of 468 patients with advanced breast cancer in a clinical trial of paclitaxel, nab-pac  ...[more]

Similar Datasets

| S-EPMC7064382 | biostudies-literature
| S-EPMC5856614 | biostudies-literature
2018-04-01 | GSE40622 | GEO
| S-EPMC5711539 | biostudies-literature
| S-EPMC8178799 | biostudies-literature
| S-EPMC4155431 | biostudies-other
| S-EPMC11339397 | biostudies-literature
| S-EPMC5050068 | biostudies-literature
| S-EPMC7785047 | biostudies-literature